Schultze A Eric, Carpenter Kent H, Wians Frank H, Agee Sara J, Minyard Jennifer, Lu Quynh Anh, Todd John, Konrad Robert J
Department of Pathology, Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, IN 46285, USA.
Toxicol Pathol. 2009 Oct;37(6):754-60. doi: 10.1177/0192623309343777. Epub 2009 Aug 21.
Serum cardiac troponin-I has been validated as a biomarker for cardiotoxicity in numerous animal models; however, baseline reference ranges for cTnI concentration in a healthy population of laboratory rats, as well as an investigation of biological cTnI variability in rats with respect to time, handling, and placebo dosing methods, have not been reported. In this study, we used an ultrasensitive cTnI immunoassay to quantify hourly concentrations of cTnI in live rats handled under standard laboratory conditions using 15 microL of serum per determination. The baseline reference range (mean 4.94 pg/mL, range 1-15 pg/mL, 99% confidence interval [CI]) of cTnI concentration in rats was consistent with previously reported reference ranges for cTnI in humans (1-12 pg/mL) and with preliminary studies in dogs (1-4 pg/mL) and monkeys (4-5 pg/mL) using the same cTnI assay method. In addition, cTnI concentrations in individual rat serum samples show minimal biological variability over a twenty-four-hour interval when compared to a meaningful reference change value of 193% to 206%. Furthermore, measurements of cTnI concentration were consistent within the reference limits in individual rats over long periods and under three different standard laboratory handling conditions. Thus, using this new method, rats can be followed longitudinally at hourly intervals, and a doubling of cTnI concentration would be significant above biological variability. This is a new paradigm for preclinical testing, which allows transient changes in cTnI concentration to be accurately quantified. This understanding of baseline and biological variability in rats will be fundamental for designing and analyzing future studies that assess potential cardiotoxicity in drug development.
血清心肌肌钙蛋白I已在众多动物模型中被确认为心脏毒性的生物标志物;然而,关于实验室大鼠健康群体中cTnI浓度的基线参考范围,以及大鼠体内cTnI在时间、处理方式和安慰剂给药方法方面的生物学变异性研究尚未见报道。在本研究中,我们使用超灵敏cTnI免疫测定法,对在标准实验室条件下处理的活大鼠每小时的cTnI浓度进行定量,每次测定使用15微升血清。大鼠cTnI浓度的基线参考范围(平均值4.94 pg/mL,范围1 - 15 pg/mL,99%置信区间[CI])与先前报道的人类cTnI参考范围(1 - 12 pg/mL)以及使用相同cTnI测定方法对狗(1 - 4 pg/mL)和猴子(4 - 5 pg/mL)的初步研究结果一致。此外,与有意义的参考变化值193%至206%相比,单个大鼠血清样本中的cTnI浓度在24小时内显示出最小的生物学变异性。此外,在长时间以及三种不同的标准实验室处理条件下,单个大鼠的cTnI浓度测量值在参考范围内保持一致。因此,使用这种新方法,可以每小时对大鼠进行纵向跟踪,cTnI浓度翻倍将显著高于生物学变异性。这是临床前测试的一种新范式,它能够准确量化cTnI浓度的瞬时变化。对大鼠基线和生物学变异性的这种理解对于设计和分析未来评估药物开发中潜在心脏毒性的研究至关重要。